Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy
Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ:...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Molecular Partners AG (“Molecular Partners” or “the Company”)...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or...
/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Molecular Partners AG (NASDAQ:...
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN) of a class action...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i)...
/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Molecular Partners AG (NASDAQ: MOLN)...
/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Molecular Partners AG (NASDAQ:...